246 related articles for article (PubMed ID: 25958230)
1. Cerebrospinal fluid tau proteins in status epilepticus.
Monti G; Tondelli M; Giovannini G; Bedin R; Nichelli PF; Trenti T; Meletti S; Chiari A
Epilepsy Behav; 2015 Aug; 49():150-4. PubMed ID: 25958230
[TBL] [Abstract][Full Text] [Related]
2. Role of cerebrospinal fluid tau protein levels as a biomarker of brain injury in pediatric status epilepticus.
Sood S; Azad C; Kaur J; Kumar P; Guglani V; Singla S
Int J Neurosci; 2023 Jul; 133(7):782-790. PubMed ID: 34473934
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid biomarkers of β-amyloid metabolism and neuronal damage in epileptic seizures.
Shahim P; Rejdak R; Ksiazek P; Blennow K; Zetterberg H; Mattsson N; Rejdak K
Eur J Neurol; 2014 Mar; 21(3):486-91. PubMed ID: 24372994
[TBL] [Abstract][Full Text] [Related]
4. Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.
Chiaravalloti A; Barbagallo G; Ricci M; Martorana A; Ursini F; Sannino P; Karalis G; Schillaci O
Brain Res; 2018 Jan; 1678():116-122. PubMed ID: 29066367
[TBL] [Abstract][Full Text] [Related]
5. Effect of epileptic seizures on the cerebrospinal fluid--A systematic retrospective analysis.
Tumani H; Jobs C; Brettschneider J; Hoppner AC; Kerling F; Fauser S
Epilepsy Res; 2015 Aug; 114():23-31. PubMed ID: 26088882
[TBL] [Abstract][Full Text] [Related]
6. Idiopathic normal-pressure hydrocephalus, cerebrospinal fluid biomarkers, and the cerebrospinal fluid tap test.
Kang K; Ko PW; Jin M; Suk K; Lee HW
J Clin Neurosci; 2014 Aug; 21(8):1398-403. PubMed ID: 24836892
[TBL] [Abstract][Full Text] [Related]
7. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.
Cysique LA; Hewitt T; Croitoru-Lamoury J; Taddei K; Martins RN; Chew CS; Davies NN; Price P; Brew BJ
BMC Neurol; 2015 Apr; 15():51. PubMed ID: 25880550
[TBL] [Abstract][Full Text] [Related]
8. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
[TBL] [Abstract][Full Text] [Related]
9. Increased total-Tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patients.
de Bont JM; Vanderstichele H; Reddingius RE; Pieters R; van Gool SW
Eur J Paediatr Neurol; 2008 Jul; 12(4):334-41. PubMed ID: 17951083
[TBL] [Abstract][Full Text] [Related]
10. Small cisterno-lumbar gradient of phosphorylated Tau protein in geriatric patients with suspected normal pressure hydrocephalus.
Djukic M; Spreer A; Lange P; Bunkowski S; Wiltfang J; Nau R
Fluids Barriers CNS; 2016 Aug; 13(1):15. PubMed ID: 27581842
[TBL] [Abstract][Full Text] [Related]
11. Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid.
Obeid R; Kasoha M; Knapp JP; Kostopoulos P; Becker G; Fassbender K; Herrmann W
Clin Chem; 2007 Jun; 53(6):1129-36. PubMed ID: 17384003
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
13. Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study.
Brockmann K; Schulte C; Deuschle C; Hauser AK; Heger T; Gasser T; Maetzler W; Berg D
Parkinsonism Relat Disord; 2015 Dec; 21(12):1427-34. PubMed ID: 26475624
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Amyloid-β and Axonal Degeneration Pathology in Delirium.
Idland AV; Wyller TB; Støen R; Eri LM; Frihagen F; Ræder J; Chaudhry FA; Hansson O; Zetterberg H; Blennow K; Bogdanovic N; Brækhus A; Watne LO
J Alzheimers Dis; 2017; 55(1):371-379. PubMed ID: 27662296
[TBL] [Abstract][Full Text] [Related]
16. Progranulin levels in status epilepticus as a marker of neuronal recovery and neuroprotection.
Huchtemann T; Körtvélyessy P; Feistner H; Heinze HJ; Bittner D
Epilepsy Behav; 2015 Aug; 49():170-2. PubMed ID: 26211941
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid biomarkers in patients with central nervous system infections: a retrospective study.
Di Stefano A; Alcantarini C; Atzori C; Lipani F; Imperiale D; Burdino E; Audagnotto S; Mighetto L; Milia MG; Di Perri G; Calcagno A
CNS Spectr; 2020 Jun; 25(3):402-408. PubMed ID: 31130152
[TBL] [Abstract][Full Text] [Related]
18. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
19. Amyloid-β and Tau Dynamics in Human Brain Interstitial Fluid in Patients with Suspected Normal Pressure Hydrocephalus.
Herukka SK; Rummukainen J; Ihalainen J; von Und Zu Fraunberg M; Koivisto AM; Nerg O; Puli LK; Seppälä TT; Zetterberg H; Pyykkö OT; Helisalmi S; Tanila H; Alafuzoff I; Hiltunen M; Rinne J; Soininen H; Jääskeläinen JE; Leinonen V
J Alzheimers Dis; 2015; 46(1):261-9. PubMed ID: 25720406
[TBL] [Abstract][Full Text] [Related]
20. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
